Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Address correspondence to: Sanjeev Noel, 720 Rutland Avenue, Ross 970, Baltimore, Maryland 21205, USA. Phone: 443.287.2703; Email: email@example.com.
Published October 14, 2019 - More info
We hypothesized that the store-operated calcium entry (SOCE) channel, Orai1, participates in the activation of Th17 cells and influences renal injury. In rats, following renal ischemia/reperfusion (I/R), there was a rapid and sustained influx of Orai1+ CD4 T cells and IL-17 expression was restricted to Orai1+ cells. When kidney CD4+ cells of post–acute kidney injury (post-AKI) rats were stimulated with angiotensin II and elevated Na+ (10–7 M/170 mM) in vitro, there was an enhanced response in intracellular Ca2+ and IL-17 expression, which was blocked by SOCE inhibitors 2APB, YM58483/BTP2, or AnCoA4. In vivo, YM58483/BTP2 (1 mg/kg) attenuated IL-17+ cell activation, inflammation, and severity of AKI following either I/R or intramuscular glycerol injection. Rats treated with high-salt diet (5–9 weeks after I/R) manifested progressive disease indicated by enhanced inflammation, fibrosis, and impaired renal function. These responses were significantly attenuated by YM58483/BTP2. In peripheral blood of critically ill patients, Orai1+ cells were significantly elevated by approximately 10-fold and Th17 cells were elevated by approximately 4-fold in AKI versus non-AKI patients. Further, in vitro stimulation of CD4+ cells from AKI patients increased IL-17, which was blocked by SOCE inhibitors. These data suggest that Orai1 SOCE is a potential therapeutic target in AKI and CKD progression.
Purvi Mehrotra, Michael Sturek, Javier A. Neyra, David P. Basile
A strong Th17 inflammatory response aggravates ischemia reperfusion–induced (IR-induced) acute kidney injury (AKI), tissue fibrosis, and AKI-to–chronic kidney disease (CKD) progression. However, the underlying mechanisms of sustained Th17 activation following AKI and during AKI-to-CKD progression are unclear. In this issue of the JCI, Mehrotra et al. present compelling evidence that the store-operated calcium (Ca2+) channel Orai1 sustains Th17-driven inflammatory response after AKI and drives the AKI-to-CKD transition. Orai1 blockade significantly protected renal function from IR, attenuated high-salt–induced AKI-to-CKD progression in rats, and decreased Th17 response in rat and human T cells. Therapeutic targeting of Orai1 can potentially reduce AKI, AKI-to-CKD progression, and other Th17-driven diseases.
Acute kidney injury (AKI) affects 2%–5% of hospitalized patients and increases the risk of adverse long-term effects, such as development of chronic kidney disease (CKD) and progression to end-stage renal disease. Additionally, AKI occurs in more than 50% of intensive care unit (ICU) patients (1). There is a complex interplay between multiple pathophysiologic mechanisms, including recruitment and activation of immune cells, which drives AKI pathogenesis (2, 3). T cells were first implicated in the pathophysiology of AKI approximately two decades ago (4), and follow-up studies identified CD4+ T cells as the major pathogenic T cell subset (5). Broadly, CD4+ T cells differentiate into proinflammatory Th1 cells (IFN-γ+ Tbet+) and Th17 cells (IL-17+, RORγT+), or antiinflammatory Th2 cells (IL-4+, GATA3+) and Tregs (IL-10+, FOXP3+), depending on the type of the initial insult and the cytokine microenvironment in the injured/infected tissue. Many other Th cells such as Th9, Th22, and T follicular helper (Tfh) have also been identified (6).
Ischemia reperfusion (IR) injury, the most common cause of AKI, is believed to predominantly elicit a Th1 proinflammatory response (7). However, more recent studies indicate involvement of a strong Th17 component (8, 9). When antigen presenting cells (APCs) produce TGF-β, IL-6, and IL-1β, naive CD4+ T cells differentiate into Th17 cells. This further activates transcription factors RORγT and STAT3 and production of Th17 signature cytokines IL-17, IL-22, and IL-21. These Th17 cytokines help recruit and activate additional proinflammatory immune cells such as monocytes and neutrophils to the injured site. Additional studies demonstrated that high-salt intake following an AKI episode reactivates Th17 cells and aggravates tissue fibrosis (10, 11). However, the underlying mechanism of sustained Th17 activation in AKI, especially following high-salt intake, is unclear. Furthermore, cellular and molecular mechanisms involved in AKI-to-CKD progression are not completely understood. These basic questions prompted Mehrotra and colleagues to explore the role of the store-operated calcium (Ca2+) channel Orai1 in Th17 differentiation and activation. Their data provide compelling evidence that Ca2+ influx by Orai1 is an important mechanism that sustains the Th17-driven inflammatory response after AKI, and drives the AKI-to-CKD transition (12).
Ca2+ release–activated Ca2+ (CRAC) channels are membrane proteins that are important for controlling Ca2+ concentration in almost all eukaryotic cells. CRAC gets activated following depletion of endoplasmic reticulum (ER) Ca2+, and this capacitative mechanism is generally referred to as store-operated Ca2+ entry (SOCE). In T cells, SOCE is initiated when an antigen binds to Fc receptors and activates phospholipase C (PLC). Activation of PLC generates second messenger inositol trisphosphate (IP3), which causes Ca2+ release from ER lumen (13). This reduction in ER Ca2+ is sensed by stromal interaction molecule (STIM) proteins, which undergo oligomerization and translocate adjacent to the plasma membrane. At these ER-plasma membrane juxtapositions, STIM protein multimers bind to Orai1. Orai1, the primary pore-forming subunit of CRAC, exists in two variants: the longer Orai1α form that contains extra 63 N-terminal amino acids, upstream of the shorter Orai1β (14). The Orai channel proteins (Orai1, 2, and 3) along with STIM proteins (STIM1 and 2) are involved in receptor-regulated Ca2+ signaling in immune cell differentiation, gene regulation, and effector function. For example, STIM1-Orai1 clusters and Ca2+ flux regulate the intensity of nuclear signaling, thereby selectively recruiting different Ca2+-dependent transcription factors (15). Mutations in ORAI1 and STIM1 genes result in defective Ca2+ signaling in T cells and are associated with impaired T cell activation and severe combined immunodeficiency in humans, reflecting their importance in several autoimmune and inflammatory diseases (16–18).
In this issue of the JCI, Mehrotra et al. (12) tested the hypothesis that Orai1 participates in the activation of Th17 cells and influences the course of renal injury (Figure 1). They initially conducted a series of in vitro and in vivo studies to explore the mechanistic role of Orai1 in Th17 differentiation, AKI pathogenesis, and AKI-to-CKD progression in rats. They then extended their findings to peripheral blood mononuclear cells (PBMCs) from critically ill ICU patients who developed AKI. The authors reported a significant expansion of Orai1-expressing CD4+ T cells 48 hours after IR, which was restricted to IL-17–expressing cells. Interestingly, Orai1 expression remained elevated in post-AKI CD4+ T cells for up to a week, while Th17 response returned to baseline. Based on these observations, the authors speculated that sustained Orai1 expression in post-AKI CD4+ T cells boosts Th17 reactivation to a subsequent insult. In fact, in vitro stimulation of post-AKI CD4+ T cells with angiotensin II (Ang II) and sodium (Na+) increased intracellular Ca2+, RORγT activity, and IL-17 (mRNA and protein) expression. These results were substantiated by in vivo AKI-to-CKD studies in rats where high-salt administration after IR aggravated chronic renal inflammation, fibrosis, and impaired renal function. Importantly, SOCE inhibitor YM58483, in the presence or absence of high salt, attenuated IR, and glycerol induced Th17 response and renal inflammation and conserved renal structure. In vitro, translational studies on PBMCs from critically ill patients showed increased frequency of ORAI1-expressing cells as well as Th17 cells that further increased under high-salt conditions. These responses were blocked by YM58483, suggesting potential therapeutic applicability of ORAI1 targeting in AKI and AKI-to-CKD progression in humans.
Major events during Orai1-mediated Th17 differentiation in AKI. (A) In resting CD4+ T cells, Orai1 is in a closed confirmation and Ca2+ is confined to the ER lumen. Following IR, Orai1 expression increases. With subsequent increase in intracellular Ca2+, RORγT activity and IL-17 production drives Th17 differentiation and AKI pathogenesis. Simultaneously, antigen binding to the TCR triggers ER Ca2+ release, likely via the PLC/IP3 pathway. STIM1, sensing loss of ER Ca2+, translocates to the plasma membrane and activates CRAC protein, resulting in Orai1 opening. Exposure to high Ang II and Na+ following AKI reactivates the Th17 response in predominantly Orai1+ cells and sustains inflammation to drive AKI to CKD. (B) CRAC inhibitors, such as YM58483/BTP2, block Ca2+ influx through Orai1 and may protect from AKI and limit the AKI-to-CKD transition.
CRAC-mediated, short-term increase in intracellular Ca2+ is critical for the stable T cell and APC interactions seen during the formation of an immunological synapse, whereas long-term elevated Ca2+ levels are required to achieve T cell effector functions (19). Intracellular ER Ca2+ efflux and CRAC-mediated influx have also been implicated in apoptosis and other related cell death mechanisms in T cells (20). The exciting findings by Mehrotra and colleagues implicate Orai1-mediated Ca2+ channeling as a key mechanism for Th17 differentiation and inflammatory response during AKI, and possibly during AKI-to-CKD transition. In a recent study, Ca2+ signaling was found to control pathogenic Th17-driven inflammation by regulating mitochondrial function, suggesting additional mechanisms are involved in Th17 responses (21). Another recent study, by Mai et al., found a protective effect of Orai1 blockade in a model of high-fat diet–induced interstitial fibrosis in ApoE-deficient mice, as well as in a model of unilateral ureteral obstruction (UUO) kidney injury in mice (22). Thus, Th17 cell–specific blocking of Orai1 could provide a unique therapeutic opportunity for targeting AKI and ameliorating the effect of a high-salt diet in AKI-to-CKD transition in humans. Furthermore, Th17 targeting in other kidney diseases where the Th17 response is active, such as proliferative glomerulonephritis, could have beneficial effects. However, Orai1 blockade can lead to impairment of T cell receptor–mediated (TCR-mediated) homeostatic T cell functions, and should be considered while translating these finding to humans. Additionally, the current study noted a significant increase in creatinine clearance in YM58483-treated rats at the end of the study; however, the authors didn’t provide a context to relate clearance to kidney function, or explore long-term consequences of the compound (12). Additionally, Orai1 has been described in CD8+ cells, B cells, NK cells, macrophages, and vascular cells. Recent studies indicate that regulatory Th17 (Treg Th17) cells, distinct from traditional proinflammatory Th17 cells, play an important role in autoimmune diseases. Therefore, it is pertinent to decipher the role of Orai1 in non–T cells, as well as in regulatory T cells, and the more recently identified double-negative (DN) T cells, for developing novel inhibitors that can specifically inhibit Th17 Orai1. Although the authors did not observe any change in other Orai proteins (Orai2 and 3) in Th17 cells in their present study, a careful examination of the role of those proteins in renal Treg cells and DN T cells, which predominantly drive antiinflammatory responses during early injury and possibly in the repair and regeneration processes after AKI, will be important (23, 24). Furthermore, it is crucial to investigate renal T cells from AKI patients and compare the responses observed by the authors in PBMCs from ICU patients.
The present findings by Mehrotra et al. highlight Orai1 as a novel mechanism in Th17-driven inflammation with significant therapeutic potential for targeting AKI, AKI-to-CKD progression, and other Th17-driven inflammatory and autoimmune diseases. However, due to widespread occurrence of Orai1 in multiple cell types and its role in homeostatic Ca2+ signaling, blocking Orai1 will require extensive future explorations, especially in humans, to develop the most promising and safe therapeutic strategy. Alternatively, modulating Orai1 function indirectly through targeting Ca2+/cAMP signaling, which inactivates Orai1 at the end of a signaling loop, may address specificity and circumvent potential adverse effects associated with direct Orai1 blocking (25). Finally, employment of novel technologies, such as single-cell RNA sequencing, T cell–specific Orai1 knockout mice, and CRISPR/Cas9 (26), will greatly enhance our understanding of the biological roles of Orai1 and assist in the development of novel inhibitors to treat AKI-to-CKD progression.
The author acknowledges support from NIH grants R01DK111209 and R01DK104662.
Conflict of interest: The author has declared that no conflict of interest exists.
Copyright: © 2019, American Society for Clinical Investigation.
Reference information: J Clin Invest. 2019;129(11):4583–4586. https://doi.org/10.1172/JCI131935.
See the related article at Calcium channel Orai1 promotes lymphocyte IL-17 expression and progressive kidney injury.